Erythropoiesis-stimulating agents (ESAs) increase Hb levels and reduce transfusion requirements in patients with cancer (Littlewood et al, 2001; Österborg et al, 2002; Vansteenkiste et al, 2002). This evidence concerns the gene GSTM1 and cancer.